New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
10:12 EDTAVGO, RDY, ENOC, LLY, YUM, BGS, VRA, TSO, RFMD, MCHP, MTB, HBC, GLF, FRME, DRC, BBEP, CRLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Avago (AVGO) upgraded to Buy from Neutral at Goldman... BreitBurn Energy (BBEP) upgraded to Neutral from Underperform at Credit Suisse... Charles River Labs (CRL) upgraded to Outperform from Market Perform at Wells Fargo... Dresser-Rand (DRC) upgraded to Positive from Neutral at Susquehanna... First Merchants (FRME) upgraded to Outperform from Market Perform at Keefe Bruyette... GulfMark Offshore (GLF) upgraded to Outperform from Market Perform at Wells Fargo... HSBC (HBC) upgraded to Buy from Hold at Deutsche Bank... M&T Bank (MTB) upgraded to Outperform from Market Perform at Keefe Bruyette... Microchip (MCHP) upgraded to Neutral from Sell at Goldman... RF Micro Devices (RFMD) upgraded to Overweight from Equal Weight at Barclays... Tesoro (TSO) upgraded to Outperform from Neutral at Credit Suisse... Vera Bradley (VRA) upgraded to Buy from Hold at Jefferies... B&G Foods (BGS) upgraded to Outperform from Sector Perform at RBC Capital... Yum! Brands (YUM) upgraded to Buy from Neutral at Goldman... Charles River Labs (CRL) upgraded to Overweight from Neutral at JPMorgan... Eli Lilly (LLY) upgraded to Neutral from Underperform at Cowen... EnerNOC (ENOC) upgraded to Outperform from Market Perform at Raymond James... Dr. Reddy's Labs (RDY) upgraded to Outperform from Neutral at Credit Suisse.
News For AVGO;BBEP;DRC;FRME;GLF;HBC;MTB;MCHP;RFMD;TSO;VRA;BGS;YUM;LLY;ENOC;RDY;CRL From The Last 14 Days
Check below for free stories on AVGO;BBEP;DRC;FRME;GLF;HBC;MTB;MCHP;RFMD;TSO;VRA;BGS;YUM;LLY;ENOC;RDY;CRL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 27, 2014
07:34 EDTAVGOAvago Q3 results likely to beat expectations, says Oppenheimer
Subscribe for More Information
06:42 EDTLLYEli Lilly initiated with a Buy at Deutsche Bank
Target $71.
August 26, 2014
09:07 EDTLLYEli Lilly announces Jardiance available in U.S. pharmacies
Subscribe for More Information
August 25, 2014
07:40 EDTRFMDRF Micro Devices weakness a buying opportunity, says Brean Capital
Brean Capital said the recent weakness in RF Micro Devices is a buying opportunity, as it sees the mix shift to 4G is driving RF content growth and notes that the company had factored in a conservative contribution from China in its guidance. Shares of RF Micro Devices are Buy rated with a $14 price target.
August 22, 2014
16:05 EDTDRCDresser-Rand not currently running formal sales process, dealReporter says
Subscribe for More Information
13:19 EDTRFMDRF Micro Devices weakness a buying opportunity, says Brean Capital
Subscribe for More Information
11:17 EDTRFMD, AVGOPeregrine unlikely to receive competing bid, says Oppenheimer
Oppenheimer believes Peregrine (PSMI) is unlikely to receive a competing takeover bid to Murata's since Murata is Peregrine's largest customer and Avago (AVGO) and Skyworks (SWKS) are looking to diversify away from mobile. Opco thinks Murata may look to divest Peregrine's non-mobile business, and views Skyworks, RF Micro Devices (RFMD), Analog Devices (ADI), and M/A-Com Technology (MTSI) as logical buyers for the business.
August 21, 2014
17:00 EDTAVGOAvago files to sell $1B of 2% convertible senior notes due 2021
Subscribe for More Information
09:00 EDTAVGOSeveral semi companies have positive read through from deal, says Sterne Agee
After Infineon (IFNNY) bought International Rectifier (IRF), Sterne Agee thinks the deal indicates that the shares ofother players in the sector - including Spansion (CODE), NXP Semiconductors (NXPI), and Avago (AVGO) - can rise further. The firm keeps Buy ratings on the latter three stocks.
07:12 EDTLLYEli Lilly announces results from pivotal UNCOVER studies for ixekizumab
Eli Lilly announces that its investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies. Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. Skin clearance was measured by standard primary endpoints for psoriasis studies: the Psoriasis Area and Severity Index and the Static Physician Global Assessment. For patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI score at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. For comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100. Adverse events were comparable for patients receiving ixekizumab in the 12-week, randomized control portion across all three studies.
August 20, 2014
08:53 EDTCRLCharles River Labs has reached attractive entry point, says Sterne Agee
Sterne Agee continues to believe that Charles River should generate high incremental margins and disproportionate growth in earnings relative to its sales growth. The firm keeps a $71 price target and Buy rating on the shares.
August 19, 2014
17:32 EDTTSOTesoro-Savage project deadline extended to March 2, 2015, Bloomberg says
Subscribe for More Information
12:34 EDTBBEPBreitBurn Energy, QR Energy receive early termination of HSR waiting period
Subscribe for More Information
08:36 EDTENOCEnerNOC announces investment in WeSpire
Subscribe for More Information
06:29 EDTAVGOMorgan Stanley remains a buyer of Avago
Subscribe for More Information
06:02 EDTYUMTaco Bell introducing dollar menu, LA Times reports
Taco Bell (YUM) is introducing its new Dollar Cravings menu, which features 11 items, the LA Times reports. McDonald's (MCD) and Wendy's (WEN) both offer dollar menus. Reference Link
August 18, 2014
17:37 EDTLLYFDA grants tentative approval for Lilly, Boehringer Basaglar insulin
Subscribe for More Information
11:41 EDTLLYCubist rises after report sparks takeover interest speculation
Subscribe for More Information
10:29 EDTAVGOGoldman cuts sector view on semiconductors to Cautious
Subscribe for More Information
08:04 EDTAVGOSemiconductors sector downgraded to Cautious from Neutral at Goldman
Goldman downgraded the Semiconductors sector to Cautious given signs the cycle is turning based on expectations for a slowdown in semiconductor revenue growth, above trend semi unit shipments that should normalize, and stretching lead times. As a result, the analyst sees risk to Q4 estimates and sees further downside of 10%-25% for the SOX (SOX) and downgraded NXP Semiconductors (NXPI) to Sell from Neutral, InvenSense (INVN) to Neutral from Buy, and removed Maxim Integrated (MXIM) from the Conviction Buy List.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use